Manulife Singapore has embarked on significant partnerships to enhance the health offerings available to its eligible customers. In one such collaboration, it has joined forces with Guardant Health, a leading precision oncology company. Through this alliance, Manulife Singapore will provide access to the Guardant360 liquid biopsy test, which is set to play a crucial role in cancer care.
The Guardant360 test is designed to offer comprehensive genomic profiling for all advanced solid cancers. By simply drawing blood, it can identify guideline-recommended biomarkers. What’s remarkable is that the results are made available within just seven days after the sample is received. This addresses a significant concern for patients who don’t have enough tumour tissue for standard biopsies, thereby potentially improving clinical outcomes for those with advanced solid tumour cancers and supporting more personalized treatment approaches.
In another important partnership, Manulife Singapore has teamed up with AMILI, Southeast Asia’s first gut microbiome insights company. This collaboration will enable eligible customers to access advanced gut microbiome screening. The screening delves into the trillions of bacteria present in an individual’s gut, providing personalized insights that can help improve aspects like immunity, brain health, and nutrition. AMILI’s test capitalizes on the region’s largest multi-ethnic Asian gut microbiome database to offer precise insights tailored to the Asian population. Moreover, customers will receive a complimentary session with AMILI physicians to help them understand their results and adopt a holistic approach to enhancing their overall well-being. Details regarding eligibility and redemption for these services will be announced at a later date.
Related topics
